Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.57 |
| ▸ | MAOA | P21397 | 8/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533369 | 0.95 | MAOB (0.62) | MAOBMAOATSHRMAPTALDH1A1 | |
| SCHEMBL13533384 | 0.93 | MAOB (0.59) | MAOBMAOATSHRMEN1KMT2A | |
| SCHEMBL13251240 | 0.88 | MAOB (0.60) | MAOBMAOATSHRMAPTMEN1 | |
| SCHEMBL13533381 | 0.88 | MAOB (0.64) | MAOBMAOATSHRMAPK1 | |
| SCHEMBL13533371 | 0.85 | MAOB (0.43) | MAOBMAOATSHRSMN1; SMN2 | |
| SCHEMBL13533374 | 0.83 | MAOB (0.43) | MAOBMAOATSHRSMN1; SMN2 | |
| SCHEMBL13533377 | 0.83 | MAOB (0.50) | MAOBMAOATSHRMAPTMEN1 | |
| SCHEMBL13534217 | 0.81 | MAOB (0.59) | MAOBMAOATSHRMAPTALDH1A1 | |
| SCHEMBL13533368 | 0.81 | MAOB (0.46) | MAOBMAOATSHR | |
| SCHEMBL13533386 | 0.80 | MAOB (0.62) | MAOBMAOATSHRMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | MAOB 306/4885MAOA 296/4885TSHR 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.